Workflow
Hypoxia Inducible Factor-2 inhibitor
icon
Search documents
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
Businesswireยท 2025-10-19 23:00
Core Insights - Taiho Pharmaceutical Co., Ltd. has exercised its option to develop and commercialize casdatifan, a small molecule HIF-2 inhibitor, in Japan and certain other Asian territories, excluding mainland China [1] Group 1 - The option exercise is based on a 2017 agreement between Taiho and Arcus Biosciences [1]